Jeff Himawan, Ph.D. has over 20 years of experience as a scientist, entrepreneur and venture capitalist and specializes in investments in the pharmaceutical sector. Jeff first joined Essex Woodlands in 1999 as an Adjunct Partner, was promoted to Partner in 2001, and was further promoted to Managing Director in 2004.
Prior to Essex Woodlands, Jeff began his industrial career in 1987 as a bench scientist at Genzyme Corporation. In 1996, Jeff co-founded Seed-One Ventures, a venture capital firm which specializes in the initial formation, financing, and early operational development of technology-based companies. As a Managing Director at Seed-One Ventures, he led the formation and management of Elusys Therapeutics, Inc., a Fund IV company.
Jeff currently serves on the Board of Directors of MediciNova, Light Sciences Oncology, Horizon Pharma and Catalyst Biosciences (CBIO) and as an Observer on the Board of Directors for Symphogen. He holds a Bachelor of Science degree from Massachusetts Institute of Technology and a Doctor of Philosophy degree from Harvard University.